New hope: expanded access to cemiplimab for cancer patients
NCT ID NCT06132191
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides expanded access to cemiplimab, an immunotherapy drug, for patients with certain solid tumors including non-small cell lung cancer, basal cell carcinoma, and cutaneous squamous cell carcinoma. The goal is to make the treatment available to those who may not have other options. Participants receive cemiplimab under a compassionate use framework.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.